Physician profile
John Frederick Payne
NPI 1740349240
$3,380.99
in general payments reported to CMS, 2019-2025
10 companies · $105 in 2025
The $105 reported for 2025 was less than what a typical Reproductive Endocrinology provider received nationally (typical 2025 total: $140).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,661 · 2020: $160 · 2021: $457 · 2022: $316 · 2023: $383 · 2024: $298 · 2025: $105.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $747 · Education: $39.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $747.08 |
| Education | $39.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tosoh Bioscience, INC. | $1,332.00 | 2019 | |
| Emd Serono, INC. | $755.84 | 2019-2025 | |
| Ferring Pharmaceuticals INC. | $276.61 | 2019-2024 | Menopur |
| Minerva Surgical, INC | $261.28 | 2021 | |
| Abbvie INC. | $203.39 | 2019-2022 | |
| Galen US INC | $181.37 | 2019-2020 | |
| Coopersurgical, INC. | $179.18 | 2022-2025 | Stripper |
| Myriad Women'S Health, INC. | $130.91 | 2023 | |
| Stryker Corporation | $41.97 | 2024 | Aequalis Perform |
| Merck Sharp & Dohme LLC | $18.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Payne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.